Myeloid Leukemia News and Research

RSS

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

Innovative breakthrough promises to diagnose DNA rearrangement mutations

Doctors are increasingly using genetic signatures to diagnose diseases and determine the best course of care, but using DNA sequencing and other techniques to detect genomic rearrangements remains costly or limited in capabilities.

28 Jan 2021

Study uses computational framework to identify tamoxifen resistance markers in ER+ breast cancer

One common challenge of cancer therapy is when cancer cells don't respond to a drug that is usually able to kill or weaken them, known as treatment resistance.

26 Jan 2021

Anti-emetic drug offers a promising approach to treat chronic myeloid leukemia

Chronic myeloid leukemia (CML) results from a degeneration of the hematopoietic stem cells (leukemia stem cells), thereby leading to the uncontrolled formation of specific white blood cells, the so-called granulocytes.

26 Jan 2021

Drug intervention may prevent heart damage caused by chemotherapy

There could be an intervention on the horizon to help prevent heart damage caused by the common chemotherapy drug doxorubicin, new research suggests.

26 Jan 2021

New maintenance treatment for AML shows strong benefit for patients

Patients with acute myeloid leukemia (AML), the most common form of acute leukemia in adults, that has gone into remission following initial chemotherapy remain in remission longer and have improved overall survival when they are given a pill form of the cancer drug azacitidine as a maintenance treatment, according to a randomized, international phase 3 clinical trial for which Weill Cornell Medicine and NewYork-Presbyterian are trial sites.

22 Jan 2021

New study helps understand molecular profile of tumors in cancer patients

Researchers from the University Hospitals in Zurich and Basel, ETH Zurich, University of Zurich and the pharmaceutical company Roche have set out to improve cancer diagnostics by developing a platform of state-of-the-art molecular biology methods.

21 Jan 2021

Investigational combo therapy shows promise in treating TP53 mutant MDS and AML patients

Myelodysplastic Syndromes (MDS) and acute myeloid leukemia (AML) are rare hematologic malignancies of the bone marrow.

21 Jan 2021

Researchers identify new drug combination that can treat acute myeloid leukemia

Scientists have identified two drugs that are potent against acute myeloid leukemia (AML) when combined, but only weakly effective when used alone.

19 Jan 2021

Researchers investigate protein phosphatase to identify new treatments for cancer, other diseases

The abundant presence of an enzyme known as low molecular weight protein tyrosine phosphatase (LMWPTP) in tumor cells has long been considered an indicator of cancer aggressiveness and metastatic potential.

13 Jan 2021

IU research findings could prevent common complication of blood stem cell transplantation in leukemia

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center published promising findings today in the New England Journal of Medicine on preventing a common complication to lifesaving blood stem cell transplantation in leukemia.

7 Jan 2021

Seniors face crushing drug costs as Congress stalls on capping Medicare out-of-pockets

Sharon Clark is able to get her life-sustaining cancer drug, Pomalyst — priced at more than $18,000 for a 28-day supply — only because of the generosity of patient assistance foundations.

4 Jan 2021

Study shows benefits of integrated palliative and oncology care for patients with advanced AML

A first-of-its-kind intervention integrating palliative care early in the course of cancer therapy for patients with advanced acute myeloid leukemia (AML), a highly aggressive cancer of the blood and bone marrow, resulted in substantial improvements in patients' quality of life, mood and end-of-life care, a team of investigators has found.

17 Dec 2020

New class of targeted cancer drugs may prove effective in treating common types of leukemia

A new study by researchers in Cleveland Clinic's Taussig Cancer Institute and Lerner Research Institute describes a novel class of targeted cancer drugs that may prove effective in treating certain common types of leukemia.

15 Dec 2020

Hematoxylin compounds can selectively kill CALR mutant cancer cells

Patients with myeloproliferative neoplasm (MPN), a group of malignant diseases of the bone marrow, often have a carcinogenic mutated form of the calreticulin gene (CALR).

10 Dec 2020

Phase I/IIA open-label study presents encouraging results on hard-to-treat AML subtypes

Novel menin-KMT2A inhibitor appears to be safe and well-tolerated. FLT3 inhibitor plus low-dose chemotherapy shows promising efficacy and safety. Results represent encouraging news on hard-to-treat AML subtypes.

7 Dec 2020

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Clinical investigators from Hackensack Meridian Health John Theurer Cancer Center (JTCC), a member of the Georgetown Lombardi Comprehensive Cancer Center consortium, are to present updates on treatment advances in multiple myeloma (MM), mantle cell lymphoma (MCL), and other types of B-cell lymphoma (BCL) as well as leukemia at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held virtually from December 5-8, 2020.

7 Dec 2020

Combination of venetoclax and standard therapies shows promise in high-risk myeloid blood cancers

The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer Institute.

7 Dec 2020

Donor stem cell transplant can improve survival rates for older patients with MDS, study shows

A new clinical trial offers the most compelling evidence to date that a donor stem cell transplant can improve survival rates for older patients with higher-risk myelodysplastic syndrome (MDS), Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology Annual Meeting.

5 Dec 2020

Study sheds light on the high burden of late effects among young survivors of acute myeloid leukemia

Adolescent and young adult (AYA) patients treated for acute myeloid leukemia (AML) have a high risk of developing several long-term health complications, a study led by UC Davis Comprehensive Cancer Center researchers has found.

9 Nov 2020

Beat AML trial achieves primary endpoint

Patients participating in The Leukemia & Lymphoma Society's (LLS) groundbreaking precision medicine Beat AML Master Clinical Trial had superior outcomes compared to acute myeloid leukemia (AML) patients who opted for standard chemotherapy treatment, according to findings published today in the prestigious Nature Medicine journal.

28 Oct 2020

Myeloid Leukemia News and Research

Innovative breakthrough promises to diagnose DNA rearrangement mutations

Study uses computational framework to identify tamoxifen resistance markers in ER+ breast cancer

Anti-emetic drug offers a promising approach to treat chronic myeloid leukemia

Drug intervention may prevent heart damage caused by chemotherapy

New maintenance treatment for AML shows strong benefit for patients

New study helps understand molecular profile of tumors in cancer patients

Investigational combo therapy shows promise in treating TP53 mutant MDS and AML patients

Researchers identify new drug combination that can treat acute myeloid leukemia

Researchers investigate protein phosphatase to identify new treatments for cancer, other diseases

IU research findings could prevent common complication of blood stem cell transplantation in leukemia

Seniors face crushing drug costs as Congress stalls on capping Medicare out-of-pockets

Study shows benefits of integrated palliative and oncology care for patients with advanced AML

New class of targeted cancer drugs may prove effective in treating common types of leukemia

Hematoxylin compounds can selectively kill CALR mutant cancer cells

Phase I/IIA open-label study presents encouraging results on hard-to-treat AML subtypes

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Combination of venetoclax and standard therapies shows promise in high-risk myeloid blood cancers

Donor stem cell transplant can improve survival rates for older patients with MDS, study shows

Study sheds light on the high burden of late effects among young survivors of acute myeloid leukemia

Beat AML trial achieves primary endpoint

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News